|
|
Post by Thundersnow on Dec 13, 2022 11:32:02 GMT -5
There's competition for the V-GO. Tandem just bought Swiss Insulin Pump Maker. SIGI Patch Pump I wonder if that's why MNKD was down early this morning? www.youtube.com/watch?v=Vkh_HWQF2os |
|
|
|
Post by Clement on Dec 13, 2022 11:51:48 GMT -5
SIGI is smart and priced accordingly.
V-GO is dumb and priced accordingly.
Apples and oranges.
|
|
|
|
Post by phdedieu12 on Dec 13, 2022 13:11:36 GMT -5
This is a year old
|
|
|
|
Post by uvula on Dec 13, 2022 14:18:42 GMT -5
The patch pump might be old but tandem just bought the company. |
|
|
|
Post by phdedieu12 on Dec 13, 2022 14:49:23 GMT -5
The patch pump might be old but tandem just bought the company. And? The point the poster made was about this product and the dip in the share price this morning. Considering it's $4.91 as we speak, I'd say it has nothing to do with it |
|
|
|
Post by sayhey24 on Dec 13, 2022 15:00:23 GMT -5
There's competition for the V-GO. Tandem just bought Swiss Insulin Pump Maker. SIGI Patch Pump I wonder if that's why MNKD was down early this morning? www.youtube.com/watch?v=Vkh_HWQF2osThe real competition for V-Go is afrezza. If afrezza was prescribed early in the diagnosis the PWD should never progress to needing the basal. The biggest market for V-Go is the medicare community. Afrezza with the pre auth is being covered at $35 for Plan D. The MNKD sales rep should be selling afrezza first as the medically correct way to treat these T2s let alone progressing to Step 4 as the first thing they lose is prandial control. If they really then need a basal many T1 afrezza users are saying they would never go back to a pump. I would think a once daily shot with Tresiba might be a better way to go than V-Go. What I will say is Mike has his hands full trying to figure out what to do with V-Go. |
|
|
|
Post by hellodolly on Dec 13, 2022 19:04:01 GMT -5
Just thinking out loud with you after I had an epiphany as I read your reply, "What I will say is Mike has his hands full trying to figure out what to do with V-Go."
Don't know why, I can't put my finger on it or recall the circumstance, likely a recent CC or investor presentation...I thought MC noted that the team is looking at something they have in mind for V-Go? My mind doesn't work as well as it did when I was 30, 40 or even 50 but, it struck me as a 'word play' on using the device for something more than just insulin. If they can partner with UTHR to deliver a DPI with their device for more than just Afrezza, why can't they partner with someone else to use their device for the delivery of __________________? Like Tyvaso, if the device is approved and the formulation is approved, a new product for V-Go won't take the traditional route with clinical trials, like Tyvaso. I'm rambling....
|
|
|
|
Post by sayhey24 on Dec 13, 2022 20:39:45 GMT -5
Here is what Mike said
"We also believe you'll start to see V-Go as a platform. I think that's something I don't want to talk about now, but as we get ready for next year, that's kind of where some of that capital can go, which is how do you re purpose V-Go outside of diabetes. And we think it's a platform device that can be leveraged for other products. So that's an area that we're looking at."
A platform for what? You can't just jam another drug into the device without trials. Is he really going to spend resources on putting something into a mechanical pump especially when he has a GLP1 which has already done phase 1s which seemed to show huge promise?
I think he just got caught up in the excitement of buying his first company and then started getting feedback afrezza and V-Go are not only competing products but are incompatible. If you believe in afrezza V-Go has no place. Mike also said they will "leverage the existing infrastructure we have. So we have 60 current Afrezza salespeople across the country, and we'll be dropping V-Go in that bag around late January." Really? This is like trying to mix oil and water. Maybe I am wrong and for the sake of the share holders I hope Mike is right and I am wrong but I will be surprised. We not only have wasted $15M+ which could be focused on afrezza and GLP1s but wasted a lot of time.
|
|
|
|
Post by sportsrancho on Dec 13, 2022 21:10:20 GMT -5
I have not heard this said anywhere, but my assumption was it’s hard to recruit sales people to sell a drug that isn’t selling, and it’s something else they can have in their sales box🤷🏼♀️ must be more to it though…
“The real competition for V-Go is afrezza.”
“If afrezza was prescribed early in the diagnosis the PWD should never progress to needing the basal.”
Yep agree with sayhey.
|
|
|
|
Post by mytakeonit on Dec 13, 2022 21:30:00 GMT -5
Didn't we all agree that Mike C bought V-Go to use the sales people and the established clientele ... no training and footwork required. That's what I remember with this wine laden mind.
But, that's mytakeonit
|
|
|
|
Post by sayhey24 on Dec 13, 2022 21:39:02 GMT -5
Sports - IDK, but I don't think there is more to the story. He is sending out sale reps who are not properly equipped to sell afrezza for a number of reasons so of course it is not selling. If we put it on costplusdrugs,com for cheap it also would not sell because the proper marketing and sales strategy has not been developed. We are $3B+ in development costs and still don't have a plan to sell into the T2 market.
Mike now has a simple gizmo the sales reps can whip out when they can't explain afrezza and the doctor says hit the bricks. Its simple, its using existing RAA and the story is simple - got an older T2 on medicare who now needs basal and prandial use this and they don't need to take MDI they just push the button at mealtime.
|
|
|
|
Post by mymann on Dec 13, 2022 21:43:54 GMT -5
V-GO is a distraction to justify Mike is doing something to improve revenue without profit. Makes the numbers look good so that the bonuses for executives at end of year can be justified. Magicians tricks.
|
|
|
|
Post by akemp3000 on Dec 13, 2022 22:13:49 GMT -5
Wow...just wow. And all while the MC team just achieved a new 52-week high. Oh well, onward and upward!
|
|
|
|
Post by Thundersnow on Dec 13, 2022 22:22:23 GMT -5
Sports - IDK, but I don't think there is more to the story. He is sending out sale reps who are not properly equipped to sell afrezza for a number of reasons so of course it is not selling. If we put it on costplusdrugs,com for cheap it also would not sell because the proper marketing and sales strategy has not been developed. We are $3B+ in development costs and still don't have a plan to sell into the T2 market. Mike now has a simple gizmo the sales reps can whip out when they can't explain afrezza and the doctor says hit the bricks. Its simple, its using existing RAA and the story is simple - got an older T2 on medicare who now needs basal and prandial use this and they don't need to take MDI they just push the button at mealtime. You really don't have a clue do you? The salespeople are well equipped with the tools to sell Afrezza but the majority of doctors are reluctant to try it because of the poor label and lack of changing their patients to a drug that PER THE LABEL is INFERIOR. We all know it works but doctors don't lurk on message boards or forums and read patients experiences. Can you imagine having your doctor say to you as the patient....I read on the INTERNET that this drug is safe and good?? Don't think so! Most doctors who have their patients under control (albeit a 7.0 - 9.0 A1C) with their therapy is very reluctant to switch to something new. Doctors are just like engineers - they don't take to CHANGE very well. Mike & Co. is working to get Afrezza widespread but we are dealing with a Bad Label, EDUCATION and BEHAVIOR with patients and doctors. All of them are not easy to convert. It will take time but I would not say the salespeople are not equipped. |
|
|
|
Post by phdedieu12 on Dec 13, 2022 22:29:28 GMT -5
Here is what Mike said "We also believe you'll start to see V-Go as a platform. I think that's something I don't want to talk about now, but as we get ready for next year, that's kind of where some of that capital can go, which is how do you re purpose V-Go outside of diabetes. And we think it's a platform device that can be leveraged for other products. So that's an area that we're looking at." A platform for what? You can't just jam another drug into the device without trials. Is he really going to spend resources on putting something into a mechanical pump especially when he has a GLP1 which has already done phase 1s which seemed to show huge promise? I think he just got caught up in the excitement of buying his first company and then started getting feedback afrezza and V-Go are not only competing products but are incompatible. If you believe in afrezza V-Go has no place. Mike also said they will "leverage the existing infrastructure we have. So we have 60 current Afrezza salespeople across the country, and we'll be dropping V-Go in that bag around late January." Really? This is like trying to mix oil and water. Maybe I am wrong and for the sake of the share holders I hope Mike is right and I am wrong but I will be surprised. We not only have wasted $15M+ which could be focused on afrezza and GLP1s but wasted a lot of time. I agree, maybe you're wrong and Mike is right, I won't be surprised. Oh and Qrum Pharma was his first acquisition, just saying... |
|
